Nexosome Oncology
PrivateLast Round
Seed
Nov 1, 2021
Total Funding Raised
$4M
Company Overview
Nexosome Oncology is a biotechnology company that develops blood tests for early-stage cancer detection using extracellular vesicle proteomics and AI/ML biomarker discovery.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Medical AI, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share, Government Contracts
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Nexosome Oncology Comps
Public and private peers based on sector, stage, and business model.
Nexosome Oncology Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Nov 1, 2021 |
Nexosome Oncology Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| DigiTx Partners | Seed |
| VisionTech Partners | Seed |
| Kentucky Science and Technology Corporation | Seed |
| Esplanade Ventures | Seed |
| XLerateHealth | Seed |
| OCA Ventures | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 1, 2021
$4M round with participation from DigiTx Partners and Esplanade Ventures.
Nexosome Oncology Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Nexosome Oncology's valuation, stock price, and market status.
